This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khorram, O. Articles by Yen, S. S. C. Search for Related Content PubMed PubMed Citation Articles by Khorram, O. Articles by Yen, S. S. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Seniors' Health

Effects of [Norleucine²⁷]Growth Hormone-Releasing Hormone (GHRH) (1–29)-NH₂ Administration on the Immune System of Aging Men and Women¹

Department of Reproductive Medicine (O.K., M.Y., L.V., S.S.C.Y.), University of California-San Diego, School of Medicine, La Jolla, California 92093-0633; and Department of Pediatrics (M.Y.), University of California, San Francisco

Address all correspondence (no reprints available) to: S. S. C. Yen, Department of Reproductive Medicine, University of California-San Diego, School of Medicine, La Jolla, California 92093-0633.

Aging in humans is associated with the decline of functional activities of the GH-insulin-like growth factor I (IGF-I) axis and the immune system. Because lymphocytes express GH-IGF-I, as well as GHRH and their respective receptors, restoration of this axis in age-advanced individuals, by the administration of GHRH, may enhance immune cell function. This hypothesis was tested by a single blind randomized placebo-controlled trial of 5 months duration, in which healthy elderly subjects (10 women, 9 men) self-administered sc nightly placebo for 4 weeks, followed by 16 weeks of [norleucine²⁷]GHRH (1–29)-NH₂ at a dose of 10 µg/kg. Fasting (0800 h–0900 h) blood samples were obtained for immune studies and for measurements of serum concentrations of IGF-I and soluble interleukin (IL)-2 receptor. GH pulsatility was determined in blood samples obtained at 10-min intervals for 12 h (2000 h–0800 h). Freshly isolated peripheral lymphocytes were analyzed by flow cytometric analysis for determination of lymphocyte subsets and monocytes. Mitogen stimulation responses, natural killer cell number and cytotoxicity, basal and stimulated IL-2 secretion from cultured lymphocytes, and IL-2 and IL-2R messenger RNA expression were measured. These studies were conducted at baseline, after placebo, and during GHRH analog administration at 4 and 16 weeks.

Treatment with GHRH analog resulted in a significant increase (107 and 70% in men and women, respectively) in the 12-h integrated GH secretion (P < .05) and serum IGF-I levels (28%) (P < .001) in both men and women by 4 weeks and lasted 12 weeks for IGF-I and 16 weeks for GH. Activation of the immune system occurred in both sexes within 4 weeks. A 30% increase (P < .001) in lymphocytes expressing the transferrin receptor (CD71) and in monocytes (CD14) (P < .05) occurred within 4 weeks. By 16 weeks, there was a significant increase (30%) in B cells (CD20) (P < .01), in cells expressing the T cell receptor /ß (20%) (P < .01), and T cell receptor / (40%) (P < .0001). There were no changes in the number of T cells (CD3), T cell subsets (CD4, CD8), or natural killer cell (CD57) over the treatment period. The increase in B cell number was associated with enhanced responsiveness (50%) to the B cell mitogens: pokeweed mitogen (P < .01 or better) and Staphylococus aureus cells (P < .001), and a transient increase at 4 weeks in circulating IgG (P < .0001), IgM, and IgA (P < .001). T cells were functionally activated, as evidenced by a 50% increase in responsiveness to phytohemagglutinin (P < .01 or better), 70% increase in the number of lymphocytes expressing the IL-2 receptor (IL-2R) (CD25) (P < .001), and enhanced IL-2R messenger RNA expression and basal IL-2 secretion (50%) (P < .05) at 16 weeks of treatment. Furthermore, circulating soluble IL-2 receptor rose significantly (15%) (P < .05) within 4 weeks of treatment and remained elevated for the duration of the study. There were no sex differences in the immune response to GHRH analog and no adverse effects. These results indicate that GHRH analog administration has profound immune-enhancing effects and may be of therapeutic benefit in states of compromised immune function.

This article has been cited by other articles:

				M. Ionescu and L. A. Frohman Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4792 - 4797. [Abstract] [Full Text] [PDF]

				E. L. Thacker, D. J. Holtkamp, A. S. Khan, P. A. Brown, and R. Draghia-Akli Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection J Anim Sci, March 1, 2006; 84(3): 733 - 742. [Abstract] [Full Text] [PDF]

				O. Khorram, M. Garthwaite, and T. Golos The Influence of Aging and Sex Hormones on Expression of Growth Hormone-Releasing Hormone in the Human Immune System J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3157 - 3161. [Abstract] [Full Text] [PDF]

				G. C. Koo, C. Huang, R. Camacho, C. Trainor, J. T. Blake, A. Sirotina-Meisher, K. D. Schleim, T.-J. Wu, K. Cheng, R. Nargund, et al. Immune Enhancing Effect of a Growth Hormone Secretagogue J. Immunol., March 15, 2001; 166(6): 4195 - 4201. [Abstract] [Full Text] [PDF]

				S. B. Solerte, M. Fioravanti, G. Vignati, A. Giustina, L. Cravello, and E. Ferrari Dehydroepiandrosterone Sulfate Enhances Natural Killer Cell Cytotoxicity in Humans Via Locally Generated Immunoreactive Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3260 - 3267. [Abstract] [Full Text]